A Phase 1 Study of TPI 287 Concurrent With Fractionated Stereotactic Radiotherapy (FSRT) in Treatment of Brain Metastases From Advanced Breast and Non-Small Cell Lung (NSCL) Cancer.

Trial Profile

A Phase 1 Study of TPI 287 Concurrent With Fractionated Stereotactic Radiotherapy (FSRT) in Treatment of Brain Metastases From Advanced Breast and Non-Small Cell Lung (NSCL) Cancer.

Suspended
Phase of Trial: Phase I

Latest Information Update: 04 Oct 2017

At a glance

  • Drugs TPI 287 (Primary)
  • Indications Brain metastases
  • Focus Adverse reactions
  • Most Recent Events

    • 28 Sep 2017 Planned End Date changed from 1 Oct 2018 to 1 Oct 2019.
    • 28 Sep 2017 Status changed from recruiting to suspended.
    • 20 Nov 2015 Results published in a Cortice Biosciences media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top